Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the target of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 154,900 shares, a growth of 92.2% from the January 15th total of 80,600 shares. Currently, 8.9% of the shares of the company are sold short. Based on an average trading volume of 366,900 shares, the days-to-cover ratio is presently 0.4 days.

Avenue Therapeutics Price Performance

NASDAQ:ATXI opened at $1.36 on Friday. The company has a market cap of $2.79 million, a P/E ratio of 0.07 and a beta of -0.28. Avenue Therapeutics has a 1 year low of $1.22 and a 1 year high of $15.00. The stock’s fifty day moving average price is $1.70 and its two-hundred day moving average price is $2.13.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Boothbay Fund Management LLC purchased a new position in Avenue Therapeutics, Inc. (NASDAQ:ATXI) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,089 shares of the company’s stock, valued at approximately $82,000. Boothbay Fund Management LLC owned approximately 2.00% of Avenue Therapeutics at the end of the most recent quarter. Institutional investors own 17.34% of the company’s stock.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.